4 February 2025 in Diabetology & Metabolic Syndrome
Probiotics serve as promising candidates in type 2 diabetes mellitus (T2DM) therapy. Not only they presumably reduce the T2DM prevalence, but also keep down its complications. In the present study, we explored the beneficial impact of ZBiotics, an engineered probiotic, on T2DM Wistar rats. In silico analysis was performed to construct a genetic-epigenetic network linked to STING-NOD pathway and autophagy signaling. Then, 30 Wistar rats were divided into 5 groups (each n = 6); normal group, diabetic model, B. subtilis, and ZBiotics treated rats at high and low doses. Experimental procedures were carried out including biochemical and histopathologic analyses. Samples were extracted from rats’ blood, liver, kidney and adipose tissues. At the molecular aspect, the molecular players, chosen by the in silico analysis, were assessed using 2–ΔΔCt to estimate their relative quantification. With immunohistochemistry, TNF-alpha and LC3B were assessed as reflectors for inflammation and autophagy respectively. ZBiotics was reported to ameliorate the T2DM-induced histological damage. Besides, it downregulated TNF-alpha and upregulated LC3B expression levels. At the biochemical aspect, ZBiotics corrected LDL-c and improved serum creatinine and CK-MB levels. Inflammation relevant genes have been downregulated regarding CHUK, NFKB1 and miR-611. Therefore, ZBiotics is speculated to operate by modulating the genetic-epigenetic network linked to inflammatory cGAS-STING and autophagy signaling. ZBiotics is recommended for clinical trials as a separate candidate or as an adjuvant to the conventional T2DM therapy.
1 June 2023 in QJM: An International Journal of Medicine
AHAmany Helmy Mohamed Hasanin
Amany Helmy Mohamed Hasanin
Background: Sorafenib is an FDA approved chemotherapeutic against Hepatocellular Carcinoma (HCC), yet associated with various resistance mechanisms. The role of high glucose status on sorafenib action is still to be elucidated. This study clarifies such interaction; taking HepG2 cell lines as HCC models, MALAT1 and H19 as molecular players. Methodology: HepG2 cell lines were purchased and classified into 8 groups. High glucose status was set by using D-glucose (33 mM) with insulin (1 µM). Mannitol (27.5 mM) was used as a negative osmotic control. Two concentrations of sorafenib were prepared; 15 µM and 20 µM. All experiments were carried out in triplicates. Cellular viability was assessed with MTT viability assay. Then, with trypan blue viability assay, the results were double checked and HepG2 morphology was examined by optical microscopy. MALAT1 and H19 RQs were assessed by real time PCR (RT-PCR). Statistical analysis was performed by SPSS software. Results: In comparison with sorafenib impact on HepG2, high glucose status drops cellular viability to 72.89% (p < 0.01). Similar outcomes occur with hyperosmolar mannitol, it decreases cellular viability to 83.13% (p < 0.001). Regarding the molecular impact, hyperosmolar mannitol with sorafenib elevates both MALAT1 and H19. Yet, high glucose status elevates MALAT1 and declines H19 (p < 0.05 and p < 0.001 for MALAT1 and H19 comparisons respectively). Conclusion: High glucose settings sensitize HepG2 to the cytotoxic impact of sorafenib and so does mannitol. This could attribute the impact of high glucose status to the hyperosmolar stress it induces on HepG2. Mannitol is recommended for further confirmatory studies either as a separate therapeutic or as an adjuvant to sorafenib.